An early SARM that got shelved partly because it can turn your night vision yellow — a side effect nobody warns you about upfront.

Scholar Rock's myostatin-blocking antibody. Myostatin is the signal telling your body to limit muscle — block it, and the hope is you keep muscle you'd otherwise lose. Being tested alongside GLP-1 drugs so the weight you drop is fat, not muscle.

An antibody that blocks the activin type II receptor — the docking station myostatin uses to tell muscle to stay small. Originally a Novartis muscle drug, now owned by Eli Lilly and being tested with semaglutide for fat loss that spares (or even adds) muscle.

Approved for horses, not humans — every 'human' use is off-label extrapolation from veterinary pharmacology, not clinical trials in people.

A synthetic fragment loosely based on a stomach-protein sequence, sold as a heal-everything injury peptide. The internet loves it; the human evidence is almost non-existent.

The 'endurance in a bottle' compound that got pulled from development after it caused cancer in animal studies — that alone should end the conversation.

A synthetic GHRH analog that tells your body to make more growth hormone. Half the GH stack, endlessly confused over 'DAC vs no-DAC,' and marketed as 'safe GH' — a phrase that's doing a lot of work.

An approved asthma drug abroad and a veterinary bronchodilator — used off-label for fat loss on the strength of stimulant side effects, not a fat-loss trial.

Originally a breast-cancer drug, now a contest-prep staple prized for a 'hard and dry' look that has nothing to do with why it was ever studied.

The 'growth hormone without the GH' combo — cleaner marketing than most, which is exactly the trap.

A naturally occurring copper-binding tripeptide with genuinely decent evidence — as a topical skincare ingredient. The moment people start injecting it as a 'youth reset,' the evidence falls off a cliff.

The 'heal faster and look better' bundle — and a textbook case of a stack name meaning different things to different people.

A selective growth-hormone secretagogue, the gentle-reputation other half of the GH stack. 'Cleaner' than the older GHRPs — which people wrongly read as 'proven safe.'

GLOW plus a 'K' — an anti-inflammatory add-on that mostly adds another unknown.

A tiny anti-inflammatory tripeptide, the 'K' bolted onto the GLOW stack to make KLOW. Sold as the gut/inflammation add-on — with essentially no human data behind it.

Bodybuilding forums treat it like a mild steroid substitute; the actual human trial shut down early on liver-enzyme and lipid concerns.

The granddaddy oral bulking steroid — huge, fast size gains and an oral 17-alpha-alkylated liver load that's why doctors stopped prescribing it decades ago.

Marketed as the 'safe' steroid because side effects are milder — milder than Trenbolone is a low bar, not a clean bill of health.

An orally active growth-hormone secretagogue — crucially, NOT a peptide, despite living in peptide forums. It genuinely raises GH and IGF-1; it also genuinely raises appetite, water retention, and blood sugar.

An approved medicine with a decades-long bodybuilding side career, best known for joint-friendly gains and a reputation for lingering hormonal aftershocks.

The 'beginner' SARM with actual human trials — milder than steroids, but 'milder' is not the same as 'safe' or 'legal.'

One of the better-studied anabolic steroids on the market, marketed as 'mild' — mild for a steroid still means real liver and lipid trade-offs.

An FDA-approved anemia drug repurposed for the fastest, biggest mass gains in the steroid world — and some of the harshest liver numbers to match.

An experimental Eli Lilly weight-loss drug hitting three gut-hormone receptors at once. In real trials it produced eye-watering fat loss — which is exactly why the grey market is selling unapproved copies of it.

One of the more hardcore SARMs on paper — and also one being studied as a male contraceptive, which tells you exactly how hard it shuts down your own hormones.

The GLP-1 drug that started the whole metabolic gold rush — approved, heavily studied, and not a grey-market mystery box. Branded semaglutide and grey powder sold as 'semaglutide' are not the same product, and regulators are blunt about it.

The 'lean and dry' contest-prep favorite, famous since the 1988 Olympics for the wrong reasons — joint pain and cholesterol swings are the quiet price tag.

Sold as an oral 'exercise mimetic'; it barely survives digestion in real life, and its actual human data is close to nonexistent.

A synthetic version of part of the thymosin beta-4 protein, sold as BPC-157's recovery sidekick. Popular in horse racing before it was popular in gyms — which tells you where the evidence comes from.

A GHRH analog that's actually FDA-approved — for a specific condition (HIV-associated belly-fat accumulation). That approval makes it a rare high-evidence peptide, and a useful yardstick for judging everything else.

The internet's favorite 'strongest SARM' claim is built almost entirely on rodent data and gym anecdotes, not people.

The original, genuinely well-studied hormone — decades of human data for low-T, but 'my doctor prescribes it' and 'I'm running physique doses on my own' are very different risk profiles.

An approved, dual-hormone diabetes and weight-loss medicine with some of the strongest human evidence in this entire category. The catch: 'tirzepatide' bought as grey-market powder is a completely different risk story from the prescribed drug.

The most powerful physique steroid there is, and the one with the loudest side effects and the least human safety data to back the legend.

Regeneron's antibody against myostatin (GDF8) — the third horse in the muscle-preservation race. Being trialled alongside semaglutide, alone and paired with a second antibody, to keep weight loss from eating your muscle.

Literally the East German state doping program's house steroid — its whole legacy is secret human experimentation, not honest clinical research.

The internet's favourite 'heal like Wolverine' combo — and its most-searched stack by a mile.

Marketed as a 'myostatin-inhibiting SARM' on the strength of test-tube and mouse data — there is essentially zero human safety record behind the hype.